The cannabinoid agonist HU-210: Pseudo-irreversible discriminative stimulus effects in rhesus monkeys

European Journal of Pharmacology

Volumn 727, Issue 1, 2014, Pages 35-42

  Hruba, Lenka ^a   McMahon, Lance R ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Apparent affinity; Cannabinoid; Drug discrimination; HU 210; Pseudo irreversible

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID RECEPTOR AGONIST; DEXANABINOL; DRONABINOL; RECEPTOR SUBTYPE; RIMONABANT; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; BENZOXAZINE DERIVATIVE; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXANOL DERIVATIVE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; RHESUS MONKEY; ANALOGS AND DERIVATIVES; ANIMAL; ANIMAL BEHAVIOR; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; PERCEPTIVE DISCRIMINATION; TIME;

ANIMALS; BEHAVIOR, ANIMAL; BENZOXAZINES; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CYCLOHEXANOLS; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; FEMALE; MACACA MULATTA; MALE; MORPHOLINES; NAPHTHALENES; PIPERIDINES; PYRAZOLES; RECEPTORS, CANNABINOID; TIME FACTORS;

EID: 84893665337     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.01.041     Document Type: Article

References (36)

1. O. Arunlakshana, and H.O. Schild Some quantitative uses of drug antagonists Br. J. Pharmacol. Chemother. 14 1959 48 58
2. M. Bidaut-Russell, W.A. Devane, and A.C. Howlett Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain J. Neurochem. 55 1990 21 26
3. B. Bosier, S. Sarre, I. Smolders, Y. Michotte, E. Hermans, and D.M. Lambert Revisiting the complex influences of cannabinoids on motor functions unravels pharmacodynamic differences between cannabinoid agonists Neuropharmacology 59 2010 503 510
4. T.H. Burkey, R.M. Quock, P. Consroe, F.J. Ehlert, Y. Hosohata, W.R. Roeske, and H.I. Yamamura Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain Eur. J. Pharmacol. 336 1997 295 298 (Pubitemid 27464878)
5. A. Cowan, J.W. Lewis, and I.R. Macfarlane Agonist and antagonist properties of buprenorphine, a new antinociceptive agent Br. J. Pharmacol. 60 1977 537 545 (Pubitemid 8149539)
6. J. De Vry, and K.R. Jentzsch Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat Eur. J. Pharmacol. 505 2004 127 133 (Pubitemid 39535684)
7. V. Di Marzo, and L. De Petrocellis Why do cannabinoid receptors have more than one endogenous ligand? Philos. Trans. R. Soc. Lond. B Biol. Sci. 367 2012 3216 3228
8. L. Fattore, and W. Fratta Beyond THC: the new generation of cannabinoid designer drugs Front. Behav. Neurosci. 5 2011 60
9. F. Ferrari, A. Ottani, and D. Giuliani Cannabimimetic activity in rats and pigeons of HU 210, a potent antiemetic drug Pharmacol. Biochem. Behav. 62 1999 75 80 (Pubitemid 29017758)
10. C.P. France, A.E. Jacobson, and J.H. Woods Discriminative stimulus effects of reversible and irreversible opiate agonists: morphine, oxymorphazone and buprenorphine J. Pharmacol. Exp. Ther. 230 1984 652 657 (Pubitemid 14040385)
11. A.N. Gifford, M. Bruneus, S.J. Gatley, R. Lan, A. Makriyannis, and N.D. Volkow Large receptor reserve for cannabinoid actions in the central nervous system J. Pharmacol. Exp. Ther. 288 1999 478 483 (Pubitemid 29119654)
12. 9-tetrahydrocannabinol-like discriminative stimulus effects in monkeys J. Pharmacol. Exp. Ther. 340 2012 37 45
13. M. Glass, and J.K. Northup Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors Mol. Pharmacol. 56 1999 1362 1369
14. M. Herkenham, A.B. Lynn, M.R. Johnson, L.S. Melvin, B.R. de Costa, and K.C. Rice Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study J. Neurosci. 11 1991 563 583
15. A.C. Howlett Pharmacology of cannabinoid receptors Annu. Rev. Pharmacol. Toxicol. 35 1995 607 634
16. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam, and R.G. Pertwee International union of pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 54 2002 161 202 (Pubitemid 34575709)
17. 9-tetrahydrocannabinol treatment in rhesus monkeys J. Pharmacol. Exp. Ther. 342 2012 843 849
18. J.J. Janoyan, J.L. Crim, and N.A. Darmani Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids Pharmacol. Biochem. Behav. 71 2002 155 162 (Pubitemid 34102474)
19. T.U.C. Järbe, A.J. Hiltunen, and R. Mechoulam Stereospecificity of the discriminative stimulus functions of the dimethylheptyl homologs of 11-hydroxy-delta 8-tetrahydrocannabinol in rats and pigeons J. Pharmacol. Exp. Ther. 250 1989 1000 1005 (Pubitemid 19246712)
20. T.P. Kenakin Pharmacologic Analysis of Drug-Receptor Interaction 1997 Raven Press New York.
21. T.P. Kenakin A Pharmacology Primer: Theory, Applications, and Methods 2009 Academic Press Massachusetts.
22. K.A. Lindborg, M.K. Teachey, S. Jacob, and E.J. Henriksen Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle Diabetes Obes. Metab. 12 2010 722 730
23. P.J. Little, D.R. Compton, R. Mechoulam, and B.R. Martin Stereochemical effects of 11-OH-delta 8-THC-dimethylheptyl in mice and dogs Pharmacol. Biochem. Behav. 32 1989 661 666 (Pubitemid 19162385)
24. L.R. McMahon Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol J. Pharmacol. Exp. Ther. 319 2006 1211 1218
25. L.R. McMahon Apparent affinity estimates of rimonabant in combination with anandamide and chemical analogs of anandamide in rhesus monkeys discriminating Delta9-tetrahydrocannabinol Psychopharmacology 203 2009 219 228
26. H. Ovadia, A. Wohlman, R. Mechoulam, and J. Weidenfeld Characterization of the hypothermic effect of the synthetic cannabinoid HU-210 in the rat. Relation to the adrenergic system and endogenous pyrogens Neuropharmacology 34 1995 175 180
27. S.L. Palmer, G.A. Thakur, and A. Makriyannis Cannabinergic ligands Chem. Phys. Lipids 121 2002 3 19 (Pubitemid 36044538)
28. L.V. Panlilio, Z. Justinova, and S.R. Goldberg Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction Pharmacol. Ther. 138 2013 84 102
29. R.G. Pertwee The pharmacology of cannabinoid receptors and their ligands: an overview Int. J. Obes. (Lond). 30 Suppl 1 2006 S13 S18
30. E. Ryberg, N. Larsson, S. Sjögren, S. Hjorth, N.O. Hermansson, J. Leonova, T. Elebring, K. Nilsson, T. Drmota, and P.J. Greasley The orphan receptor GPR55 is a novel cannabinoid receptor Br. J. Pharmacol. 152 2007 1092 1101 (Pubitemid 350166046)
31. Z.H. Song, and T.I. Bonner A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2 Mol. Pharmacol 49 1996 891 896 (Pubitemid 26146145)
32. J.L. Stewart, and L.R. McMahon Rimonabant-induced Delta9- tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs J. Pharmacol. Exp. Ther. 334 2010 347 356
33. R.J. Tallarida Drug Synergism and Dose-Effect Data Analysis 2000 Chapman and Hall/CRC Florida.
34. B.F. Thomas, A.F. Gilliam, D.F. Burch, M.J. Roche, and H.H. Seltzman Comparative receptor binding analyses of cannabinoid agonists and antagonists J. Pharmacol. Exp. Ther. 285 1998 285 292 (Pubitemid 28207598)
35. H.M. Wu, Y.M. Yang, and S.G. Kim Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of Gα i/o inhibition Mol. Pharmacol. 80 2011 859 869
36. A. Zimmer, A.M. Zimmer, A.G. Hohmann, M. Herkenham, and T.I. Bonner Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice Proc. Nat. Acad. Sci. U.S.A. 96 1999 5780 5785 (Pubitemid 29234695)